Cuban attributes the US’ high drug prices to PBMs—often considered the “middlemen” within the pharma supply chain—arguing ...

The rise of more transparent, “Cost Plus” pharmacy models is stirring debate within the pharmaceutical space as smaller players put pressure on the large PBMs. In January 2022, entrepreneur Mark Cuban ...

Avy Punwasee is a Partner at Revenue Management Labs. We help companies develop and execute pricing solutions to maximize profits. Cost-plus pricing has long been a standard method for setting product ...

Mark Cuban Cost Plus Drug Company continues to disrupt the pharmaceutical market by partnering with health systems to supply hospitals with cheap medicine. It recently announced it would also import ...

Nov 17 (Reuters) - Cost Plus Inc. shares were among the biggest losers on the Nasdaq on Friday, a day after the retailer said its quarterly loss more than quadrupled as rising costs outweighed ...

NEW YORK, Nov 1 (Reuters) - Cost Plus Inc. on Wednesday posted its smallest sales decline in several quarters at stores open at least a year, but said customers bought more low-margin items like ...